- Home
- IMCR vs MNR Comparison
IMCR vs MNR Comparison
Compare IMCR & MNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- MNR
- Stock Information
- Founded
- IMCR 2008
- MNR 2017
- Country
- IMCR United Kingdom
- MNR United States
- Employees
- IMCR N/A
- MNR N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- MNR
- Sector
- IMCR Health Care
- MNR
- Exchange
- IMCR Nasdaq
- MNR Nasdaq
- Market Cap
- IMCR 1.7B
- MNR 1.7B
- IPO Year
- IMCR 2021
- MNR 2023
- Fundamental
- Price
- IMCR $35.17
- MNR $15.07
- Analyst Decision
- IMCR Buy
- MNR Strong Buy
- Analyst Count
- IMCR 10
- MNR 3
- Target Price
- IMCR $58.13
- MNR $23.00
- AVG Volume (30 Days)
- IMCR 250.5K
- MNR 322.0K
- Earning Date
- IMCR 08-07-2025
- MNR 08-12-2025
- Dividend Yield
- IMCR N/A
- MNR 18.24%
- EPS Growth
- IMCR N/A
- MNR 705.75
- EPS
- IMCR N/A
- MNR 1.56
- Revenue
- IMCR $333,581,000.00
- MNR $941,846,000.00
- Revenue This Year
- IMCR $26.82
- MNR $5.70
- Revenue Next Year
- IMCR $8.15
- MNR $4.36
- P/E Ratio
- IMCR N/A
- MNR $9.64
- Revenue Growth
- IMCR 25.75
- MNR 22.14
- 52 Week Low
- IMCR $23.15
- MNR $12.40
- 52 Week High
- IMCR $40.88
- MNR $20.94
- Technical
- Relative Strength Index (RSI)
- IMCR 53.52
- MNR 57.59
- Support Level
- IMCR $32.20
- MNR $14.42
- Resistance Level
- IMCR $37.63
- MNR $14.89
- Average True Range (ATR)
- IMCR 1.21
- MNR 0.37
- MACD
- IMCR 0.03
- MNR 0.01
- Stochastic Oscillator
- IMCR 53.90
- MNR 60.55
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.